Clinical study on transplantation of G-CSF-mobilized allo-PBSC and allo-bone marrow for leukemia patients.
- Author:
Quan-Yi LU
1
;
Xiao-Qing NIU
;
Yong GUO
;
Peng ZHANG
;
Xiao-Xin ZHENG
;
Xiao-Fan FU
;
Juan-Juan ZHOU
Author Information
1. Department of Hematology, Teaching Hospital, Zhongshan Hospital of Xiamen, Fujian Medical University, Xiamen 361004, China. luquanyi@medmail.com.cn
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Bone Marrow Transplantation;
methods;
China;
Female;
Follow-Up Studies;
Graft vs Host Disease;
diagnosis;
Granulocyte Colony-Stimulating Factor;
therapeutic use;
Hematopoietic Stem Cell Mobilization;
methods;
Humans;
Leukemia;
therapy;
Male;
Peripheral Blood Stem Cell Transplantation;
methods;
Transplantation, Homologous;
Treatment Outcome
- From:
Journal of Experimental Hematology
2005;13(2):326-328
- CountryChina
- Language:Chinese
-
Abstract:
To study clinical outcome of G-CSF-mobilized allo-peripheral blood stem cell (PBSC) and allo-bone marrow (BM) transplantation for patients with leukemia, donors were injected G-CSF 8-10 microg/(kg.d) for 5 days, PBSC were collected on day 4-5 and G-CSF mobilized BM was extracted on day 7. Conditioning regimen consisting of fludarabine, busulfan and cyclophosphamide. The results showed that transplanted cells in all patients were engrafted, the median days of neutrophil exceeding 0.5 x 10(9)/L and platelet exceeding 20 x 10(9)/L were 10.2 days (range 9 - 12 days) and 12.5 days (range 12 - 14 days), respectively. Patients were monitored up to 100 days, 4 of 12 patients (33.3%) developed II aGVHD, 10 of 12 patients (83.3%) developed limited cGVHD. The median follow-up duration was 5 months. Two patients died, the others were alive in disease-free situation. In conclusion, allogeneic transplantation of G-CSF mobilized PBSC plus BM was safe and effective treatment for patients with leukemia, the therapy provides rapid and sustained engraftment without increase in incidence of aGVHt and cGVHD.
